Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma

Nitric oxide (NO) is able to lower intraocular pressure (IOP); however, its therapeutic effects on outflow physiology are location‐ and dose‐dependent. A NO delivery platform that directly targets the resistance‐generating region of the conventional outflow pathway and locally liberates a controlled dose of NO is reported. An increase in outflow facility (decrease in IOP) is demonstrated in a mouse model.

[1]  Brigitte Städler,et al.  A Critical Look at Multilayered Polymer Capsules in Biomedicine: Drug Carriers, Artificial Organelles, and Cell Mimics , 2011 .

[2]  E. Lütjen-Drecoll,et al.  Structural changes of the trabecular meshwork in different kinds of glaucoma. , 2009, Experimental eye research.

[3]  D. Ellis,et al.  Characterization of soluble guanylate cyclase in NO-induced increases in aqueous humor outflow facility and in the trabecular meshwork. , 2009, Investigative ophthalmology & visual science.

[4]  P. Kaufman,et al.  A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study , 2014, British Journal of Ophthalmology.

[5]  R. Weinreb,et al.  Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. , 2016, Ophthalmology.

[6]  G. Blin,et al.  Multiple Functionalities of Polyelectrolyte Multilayer Films: New Biomedical Applications , 2010, Advanced materials.

[7]  L. Schmetterer,et al.  Altered nitric oxide system in patients with open-angle glaucoma. , 2007, Archives of ophthalmology.

[8]  C. R. Ethier,et al.  Role of nitric oxide in murine conventional outflow physiology. , 2015, American journal of physiology. Cell physiology.

[9]  F. Medeiros,et al.  Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. , 2016, American journal of ophthalmology.

[10]  H. Quigley,et al.  The effects of anesthesia, mouse strain and age on intraocular pressure and an improved murine model of experimental glaucoma. , 2012, Experimental eye research.

[11]  D. Epstein,et al.  Patterns of aqueous humor outflow in glaucomatous and nonglaucomatous human eyes. A tracer study using cationized ferritin. , 1989, Archives of ophthalmology.

[12]  P. Hammond.  Building biomedical materials layer-by-layer , 2012 .

[13]  H. Möhwald,et al.  Stimuli-responsive LbL capsules and nanoshells for drug delivery. , 2011, Advanced drug delivery reviews.

[14]  B. Rowe,et al.  Measurement of Outflow Facility Using iPerfusion , 2016, PloS one.

[15]  Rona Chandrawati,et al.  Triggered cargo release by encapsulated enzymatic catalysis in capsosomes. , 2011, Nano letters.

[16]  C. R. Ethier,et al.  Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes. , 2012, Investigative ophthalmology & visual science.

[17]  D. Ellis,et al.  NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. , 2008, American journal of physiology. Cell physiology.

[18]  F. Caruso,et al.  Degradable, Surfactant‐Free, Monodisperse Polymer‐Encapsulated Emulsions as Anticancer Drug Carriers , 2009 .

[19]  Elazer R. Edelman,et al.  Adv. Drug Delivery Rev. , 1997 .

[20]  Y. H. ChangJason,et al.  Multi-Scale Analysis of Segmental Outflow Patterns in Human Trabecular Meshwork with Changing Intraocular Pressure , 2014 .

[21]  L. Teixeira,et al.  Eye , 2013, AORN journal.

[22]  David J. Calkins,et al.  The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. , 2010, Investigative ophthalmology & visual science.

[23]  Marcus Ang,et al.  Sustained drug release in nanomedicine: a long-acting nanocarrier-based formulation for glaucoma. , 2014, ACS nano.

[24]  R. Misra,et al.  Biomaterials , 2008 .

[25]  Ted S Acott,et al.  Current understanding of conventional outflow dysfunction in glaucoma , 2012, Current opinion in ophthalmology.

[26]  Brigitte Städler,et al.  Biocatalytic polymer coatings: on-demand drug synthesis and localized therapeutic effect under dynamic cell culture conditions. , 2014, Small.

[27]  Fernando Albericio,et al.  Engineering advanced capsosomes: maximizing the number of subcompartments, cargo retention, and temperature-triggered reaction. , 2010, ACS nano.

[28]  Joseph J. Richardson,et al.  Capsosomes as Long-Term Delivery Vehicles for Protein Therapeutics. , 2015, Langmuir : the ACS journal of surfaces and colloids.

[29]  Joseph J. Richardson,et al.  Technology-driven layer-by-layer assembly of nanofilms , 2015, Science.

[30]  J. Kiel,et al.  Episcleral venous pressure responses to topical nitroprusside and N-Nitro-L-arginine methyl ester. , 2010, Investigative ophthalmology & visual science.

[31]  L. Liaudet,et al.  Nitric oxide and peroxynitrite in health and disease. , 2007, Physiological reviews.

[32]  F. Caruso,et al.  Disulfide-Stabilized Poly(methacrylic acid) Capsules: Formation, Cross-Linking, and Degradation Behavior , 2008 .

[33]  A. Zelikin,et al.  Biocatalytic polymer thin films: optimization of the multilayered architecture towards in situ synthesis of anti-proliferative drugs. , 2014, Nanoscale.

[34]  H. Thieme,et al.  The regulation of trabecular meshwork and ciliary muscle contractility , 2000, Progress in Retinal and Eye Research.

[35]  Robert N. Weinreb,et al.  Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma , 2012, Nature Reviews Drug Discovery.

[36]  Frank Caruso,et al.  Nanoengineering of particle surfaces. , 2001 .

[37]  M. Marletta,et al.  Structure and regulation of soluble guanylate cyclase. , 2012, Annual review of biochemistry.

[38]  E. Ongini,et al.  Nitric oxide (NO): an emerging target for the treatment of glaucoma. , 2014, Investigative ophthalmology & visual science.

[39]  A. W. Carpenter,et al.  Nitric oxide release: part II. Therapeutic applications. , 2012, Chemical Society reviews.

[40]  F. Caruso,et al.  Binding, Internalization, and Antigen Presentation of Vaccine‐Loaded Nanoengineered Capsules in Blood , 2008 .

[41]  F. Caruso,et al.  A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. , 2009, ACS nano.

[42]  J. Haines,et al.  Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with sex and postmenopausal hormone use. , 2010, Investigative ophthalmology & visual science.

[43]  Rona Chandrawati,et al.  Biomimetic liposome- and polymersome-based multicompartmentalized assemblies. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[44]  Young H. Kwon,et al.  Novel drug delivery systems for glaucoma , 2011, Eye.

[45]  F. Paulsen,et al.  The structure of the trabecular meshwork, its connections to the ciliary muscle, and the effect of pilocarpine on outflow facility in mice. , 2014, Investigative ophthalmology & visual science.

[46]  B. G. Dijkstra,et al.  Nitric oxide/guanylate cyclase pathways and flow in anterior segment perfusion , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[47]  P. Kaufman,et al.  Effect of nitric oxide on anterior segment physiology in monkeys. , 2013, Investigative ophthalmology & visual science.

[48]  C. R. Ethier,et al.  eNOS, a pressure-dependent regulator of intraocular pressure. , 2011, Investigative ophthalmology & visual science.

[49]  F. Caruso,et al.  Noncovalent liposome linkage and miniaturization of capsosomes for drug delivery. , 2010, Biomacromolecules.

[50]  Jian-xing Ma,et al.  Nanoparticle-Assisted Targeted Delivery of Eye-Specific Genes to Eyes Significantly Improves the Vision of Blind Mice In Vivo , 2014, Nano letters.

[51]  W. Stamer,et al.  The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium. , 2009, Experimental eye research.

[52]  C. Patterson,et al.  Evidence for association of endothelial nitric oxide synthase gene in subjects with glaucoma and a history of migraine. , 2005, Investigative ophthalmology & visual science.

[53]  A. Mendes,et al.  Enzyme Prodrug Therapy Engineered into Biomaterials , 2014 .

[54]  F. Caruso,et al.  A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. , 2009, Biomaterials.

[55]  Yajun Wang,et al.  Triggered enzymatic degradation of DNA within selectively permeable polymer capsule microreactors. , 2009, Angewandte Chemie.

[56]  C. Walker.  Ophthalmology , 1859, Bristol medico-chirurgical journal.

[57]  L. Christophorou.  Science , 2018, Emerging Dynamics: Science, Energy, Society and Values.

[58]  F. Caruso,et al.  A general approach for DNA encapsulation in degradable polymer microcapsules. , 2007, ACS nano.

[59]  W. Stamer,et al.  Concentration-related effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility. , 2014, Experimental eye research.

[60]  C. R. Ethier,et al.  Outflow physiology of the mouse eye: pressure dependence and washout. , 2011, Investigative ophthalmology & visual science.

[61]  V. Torchilin,et al.  New Developments in Liposomal Drug Delivery. , 2015, Chemical reviews.

[62]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[63]  F. Caruso,et al.  Cholesterol-mediated anchoring of enzyme-loaded liposomes within disulfide-stabilized polymer carrier capsules. , 2009, Biomaterials.

[64]  J. Kiel,et al.  Modulation of choroidal autoregulation in the rabbit. , 1999, Experimental eye research.

[65]  O. Urakawa,et al.  Small - , 2007 .

[66]  E. Ongini,et al.  A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. , 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.